Sector: MedicalPONIARD PHARMACEUTIC (NASDAQ: PARD)
Ranking History
Scan Date: | 10/27/2009 |
Sector: | Medical |
Funamental : | 195 |
Technical : | 46 |
Performance : | 224 |
Overall: | 172 |
Number of Stocks: | 306 |
Scan Date: | 10/20/2009 |
Sector: | Medical |
Funamental : | 198 |
Technical : | 93 |
Performance : | 262 |
Overall: | 224 |
Number of Stocks: | 305 |
Scan Date: | 10/15/2009 |
Sector: | Medical |
Funamental : | 198 |
Technical : | 209 |
Performance : | 277 |
Overall: | 274 |
Number of Stocks: | 305 |
Headlines
- Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update
Nov 03, 2009 04:05 PM | PARD
- Poniard Pharmaceuticals to Host Third Quarter 2009 Financial Results Conference Call on November 3
Oct 27, 2009 08:31 AM | PARD
- Marc J. Fagel of the U.S. Securities and Exchange Commission to Discuss SEC Enforcement at CBI's Biotech/Pharma Finance and Accounting Forum in San Francisco
Oct 07, 2009 07:35 AM | CEGE, PARD
- Poniard Pharmaceuticals to Present at the 2009 UBS Global Life Sciences Conference
Sep 16, 2009 08:01 AM | PARD, UBS
- Poniard Pharmaceuticals Announces Pivotal Phase 3 SPEAR Trial Evaluating Picoplatin in Small Cell Lung Cancer Reaches 320th Event Target
Sep 15, 2009 08:03 AM | PARD
- Poniard Pharmaceuticals To Present at Three Upcoming Investor Conferences in September
Sep 02, 2009 08:30 AM | PARD
- 10 Extreme Trades On Pending Clinical Trial Results
May 14, 2009 11:42 AM | ARNA, CLDA, FOLD, GNTA, INSM, JAZZ
- Earnings Preview For Mar 16 - 20
Mar 13, 2009 05:32 PM | ABG, ADBE, AHR, AIR, ATU, B
- Celgene: Take The Money and Run
Mar 04, 2009 08:51 PM | ALTH, CELG, INCY, PARD, SGEN
- Rigel Pharmaceuticals– Crisis Or Opportunity?
Nov 10, 2008 09:57 AM | ABT, AGN, AMGN, CVTX, GILD, INCY
- Poniard Pharmaceuticals Secures $60 Million Committed Equity Financing Facility
Aug 20, 2009 06:05 AM | PARD
- Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update
Aug 04, 2009 04:01 PM | PARD
- Poniard Pharmaceuticals to Present at Two Upcoming Investor Conferences in August
Jul 29, 2009 08:32 AM | PARD
- Poniard Pharmaceuticals to Host Second Quarter 2009 Financial Results Conference Call on August 4
Jul 28, 2009 01:06 PM | PARD
- Poniard Pharmaceuticals Announces Positive Cardiac Safety Data From Picoplatin Phase 1 Trial Supporting NDA Filing
Jul 21, 2009 08:02 AM | PARD
- Poniard Pharmaceuticals Appoints Gary A. Lyons to Board of Directors
Jul 09, 2009 08:02 AM | PARD
- Poniard Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference
Jun 05, 2009 08:31 AM | PARD
- Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
May 28, 2009 08:03 AM | PARD
- Poniard Pharmaceuticals Announces Positive Efficacy and Safety Data From Phase 2 Clinical Trial of Picoplatin in Men With Metastatic Prostate Cancer
May 28, 2009 08:01 AM | PARD
- Poniard Pharmaceuticals Files Shelf Registration
May 15, 2009 08:00 AM | PARD
- Form 4 PONIARD PHARMACEUTICALS, For: Oct 06 Filed by: MARTELL RON (10K)
Oct 08, 2009 07:13 PM
- Form 4 WEAVER GREGORY L For: Aug 21 (10K)
Aug 21, 2009 01:43 PM
- Form 4 PONIARD PHARMACEUTICALS, For: Jul 11 Filed by: LYONS GARY A (10K)
Jul 14, 2009 03:21 PM
- Form 4 PONIARD PHARMACEUTICALS, For: Jul 07 Filed by: LYONS GARY A (10K)
Jul 09, 2009 07:48 PM
- Form 3 PONIARD PHARMACEUTICALS, For: Jul 07 Filed by: LYONS GARY A (10K)
Jul 09, 2009 07:47 PM
- Form 4 JACKSON MICHAEL K For: Jun 02 (10K)
Jun 03, 2009 05:02 PM
- Form 4 BASSO ROBERT S For: Apr 03 (10K)
Apr 07, 2009 12:08 PM
- Form 4 PONIARD PHARMACEUTICALS, For: Apr 06 Filed by: WEAVER GREGORY L (10K)
Apr 06, 2009 03:54 PM
- Form 4 PONIARD PHARMACEUTICALS, For: Mar 27 Filed by: CRAVES FRED B (10K)
Mar 30, 2009 02:46 PM
- Form 4 PONIARD PHARMACEUTICALS, For: Mar 26 Filed by: CRAVES FRED B (10K)
Mar 30, 2009 02:44 PM
Analyst Ratings
Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
Share Performance
|
Period
|
PARD
|
Compare to S&P
|
| YTD |
239.38 %
|
195.84 %
|
| 4 Weeks |
-8.52 %
|
-9.49 %
|
| 12 Weeks |
-11.73 %
|
-13.91 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 20.00 %
|
|
EPS Growth in Last Year: 22.22 %
|
|
Sales Growth in Last Quarter: -0.01 %
|
|
Sales Growth in Last Quarter: -0.01 %
|
|
